Early Returns Podcast with Jan Baran - Josh Gerstein: SCOTUS, the Presidential Immunity Case Fallout, and the Dobbs Case Leak Investigation
Podcast: Post-Dobbs - One Year Later - Diagnosing Health Care
#WorkforceWednesday: Employee and Health Benefits One Year After Dobbs - Employment Law This Week®
Reproductive Rights in the Post-Dobbs Era
Podcast: Post-Dobbs - Considerations for Clinical Trials and Research - Diagnosing Health Care
#WorkforceWednesday: 2022 – A Year in Review - Employment Law This Week®
Season Three Trailer
Let's Talk About Child Custody & Adoption in Light of the Dobbs Decision
Podcast: Post-Dobbs Access to Reproductive Health Care and Abortion-Inducing Drugs - Diagnosing Health Care
In the Boardroom With Resnick and Fuller - Episode 2
Podcast: Post-Dobbs - Navigating the Fast-Changing and Uncertain Legal Landscape - Diagnosing Health Care
Let's Talk About the Constitutional Aspects of the Dobbs Decision
What Can The Handmaid’s Tale Teach Us About Corporate Abortion Policies? - Hiring to Firing Podcast
#WorkforceWednesday: Enforcement Risk Post-Roe, 11th State Passes Paid Family and Medical Leave, FTC/NLRB Join Forces - Employment Law This Week®
Employee Benefits Post-Dobbs: What Kinds of Assistance Can Employers Now Offer in Reproductive Healthcare?
#WorkforceWednesday: Employers Respond to Dobbs, Implications of the Supreme Court's EPA Ruling, and Pay Increases for CA Health Care Workers - Employment Law This Week®
How the Dobbs Supreme Court Decision Affects Employee Benefits
Employment Law Now VI-118 - Overturning Roe v. Wade and the Impact on Employers and Employees
DE Under 3: Federal Agencies Semi-Annual Regulatory Agenda; ODEP’s NDEAM 2022 Theme & The Dobbs Decision
#WorkforceWednesday: SCOTUS Overturns Roe v. Wade - What Employers Should Consider - Employment Law This Week®
On March 26, 2024, the Supreme Court heard arguments in the two consolidated cases concerning access to mifepristone pending before the Court, FDA v. Alliance for Hippocratic Medicine, Case No. 23-235 and Danco Laboratories,...more
Nearly three months after hearing oral arguments, a divided Fifth Circuit panel issued its decision in Alliance for Hippocratic Medicine v. FDA, upholding the U.S. Food and Drug Administration’s (“FDA”) underlying approval of...more
For a brief moment in time last April, the U.S. Food and Drug Administration’s (“FDA”) approval of the commonly-used abortion medication, Mifepristone, was curtailed. Just days after a Texas federal judge’s ruling suspended...more
On Friday, April 7, both the Northern District of Texas and the Eastern District of Washington issued decisions impacting the Food and Drug Administration’s (FDA) approval of the abortion drug mifepristone. The Texas decision...more
The US Supreme Court’s June 2022 decision in Dobbs v. Jackson Women’s Health Organization — which overturned Roe v. Wade and nearly 50 years of a federal constitutional right to abortion — has had a tectonic impact. Less than...more
On January 3, 2023, FDA released an updated Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. The updated REMS follows a December 2021 FDA announcement that it would eliminate the requirement that mifepristone...more
Court Remands Remedy for Unlawful 340B Rule to HHS - On January 10, 2023, the DC District Court remanded the issue of how to remedy five years of underpayments to 340B hospitals to the Department of Health and Human...more
On January 3, 2023, the U.S. Food and Drug Administration (FDA) modified its risk evaluation and mitigation strategy (REMS) program (“Mifepristone REMS Program”) to provide a process for pharmacies to become certified to...more
Unintended downstream consequences are likely to abound in the wake of the June 24, 2022 Dobbs decision that overruled Roe v. Wade, as Mintz attorneys have addressed in other contexts here and here Those looking ahead have...more